Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This position statement will address in an evidence-based approach some of the important issues and controversies of current drug treatment of depression such as the efficacy of antidepressants, their effect on suicidality and their place in a complex psychiatric treatment strategy including psychotherapy. The efficacy of antidepressants is clinically relevant. The highest effect size was demonstrated for severe depression. Based on responder rates and based on double-blind placebo-controlled studies, the number needed to treat (NNT) is 5–7 for acute treatment and four for maintenance treatment. Monotherapy with one drug is often not sufficient and has to be followed by other antidepressants or by comedication/augmentation therapy approaches. Generally, antidepressants reduce suicidality, but under special conditions like young age or personality disorder, they can also increase suicidality. However, under the conditions of good clinical practice, the risk–benefit relationship of treatment with antidepressants can be judged as favourable also in this respect. The capacity of psychiatrists to individualise and optimise treatment decisions in terms of ‘the right drug/treatment for the right patient’ is still restricted since currently there are no sufficient powerful clinical or biological predictors which could help to achieve this goal. There is hope that in future pharmacogenetics will contribute significantly to a personalised treatment. With regard to plasma concentration, therapeutic drug monitoring (TDM) is a useful tool to optimize plasma levels therapeutic outcome. The ideal that all steps of clinical decision-making can be based on the strict rules of evidence-based medicine is far away from reality. Clinical experience so far still has a great impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“given this diversity and complexity in the aetiopathogenesis of depression and the pharmacological mechanisms of antidepressants [19,23,41,42,76,178], there is a huge variation of different responses to treatment in general, as well as of different dispositions regarding the question as to which specific antidepressan…”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“Depression is one of the most prevalent psychiatric disorders [3,206] and leads to substantial suffering of the patients, a heavy burden for the family, a high risk of suicidal behaviour (lifetime risk of suicide up to 15%) and significant socioeconomic”
BackgroundKeller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 2×
“[80] comparing the acute treatment with either nefazodone or a special short-term psychotherapy (CBASP) or both, COMBI was superior to medication alone in patients with the following diagnoses: (1) dysthymia with additional major depressive disorder (MDD), or (2) persisting MDD or (3) partially remitted MDD with poor…”
BackgroundResultClinical diagnosis of depression in primary care: a meta-analysis
Mitchell, A. J., Vaze, A., & Rao, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60879-5 · Cited by 1,251 · cited 1×
“several studies [77,95,102,106,128,195,204,205,207].”
Behavioral activation treatments of depression: a meta-analysis.
Cuijpers, P., van Straten, A., & Warmerdam, L. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.11.001 · Cited by 1,144
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 20×
“On the basis of results of routine care documentation, Parker and colleagues came to the conclusion that TCAs and monoamine oxidase inhibitors (MAOIs) are the most effective pharmacological treatments for melancholic depression, while the newer agents (SSRIs, reversible inhibitors of non-reversible monoamine oxidaseA…”
BackgroundMethodResultInfluentialAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 2×
“Regarding tolerability, Anderson looked at 95 randomised controlled studies including a total of 10,553 patients.”
BackgroundA Multifaceted Intervention to Improve Treatment of Depression in Primary Care
Katon, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830100072009 · Cited by 835
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609 · cited 2×
“None of these differences, however, are statistically significant [175].”
BackgroundSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Maintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476 · cited 1×
“depressive episode and the risk of relapse [16,44,149,198] require an effective drug treatment that simultaneously reduces suicidal”
BackgroundWilliams, Jr., Barrett, J., Oxman, T., Frank, E., Katon, W., Sullivan, M., Cornell, J., & Sengupta, A. (2000) · JAMA · doi:10.1001/jama.284.12.1519 · Cited by 460
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399 · cited 1×
“depression in the context of bipolar disorder) has to follow special rules [49].”
BackgroundSelf-citationEfficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347 · cited 2×
“Amongst others, the issue of clinically relevant efficacy [87,147], as well as the question of whether antidepressants are safe in terms of suicidality, are addressed [34,53].”
BackgroundActive placebos versus antidepressants for depression
Moncrieff, J., Wessely, S., & Hardy, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003012.pub2 · Cited by 342
Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 2×
“Especially the insufficient response in the first 14 days of therapy with antidepressants seems to be of great prognostic importance for the further therapy course as regards response and remission [63,180].”
BackgroundGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Rising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 1×
“by the inhibiting effect of R-citalopram at an allosteric transporter binding receptor [14,67,75,81,96,99,104,130,132,139,183,184].”
BackgroundSix-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
Vaiva, G., Vaiva, G., Ducrocq, F., Meyer, P., Mathieu, D., Philippe, A., Libersa, C., & Goudemand, M. (2006) · BMJ · doi:10.1136/bmj.332.7552.1241 · Cited by 279 · cited 1×
“suggested as an alternative, might be ineffective under certain circumstances [196], and may even induce suicidality themselves”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., & Haukka, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1358 · Cited by 277
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Oxford Textbook of Suicidology and Suicide Prevention
(2009) · doi:10.1093/med/9780198570059.001.0001 · Cited by 240
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192 · cited 2×
“cleft is increased due to reuptake inhibition or other pharmacological mechanisms [9,148,158].”
BackgroundWittchen, H.-U., H??fler, M., & Meister, W. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200105000-00001 · Cited by 163 · cited 1×
“several studies [77,95,102,106,128,195,204,205,207].”
Treatment of depression with atypical features: a meta-analytic approach
Henkel, V., Mergl, R., Allgaier, A.-K., Kohnen, R., Möller, H.-J., & Hegerl, U. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.07.012 · Cited by 161 · cited 1×
“The latter is especially of interest if one goes beyond the narrow field of ‘‘major depression/depressive episode’’ to the broader spectrum of depressive disorders, especially regarding subtypes which were traditionally classified as belonging to the ‘‘neurotic’’ spectrum and now appear among others under the term dys…”
BackgroundPAYKEL, E. S., SCOTT, J., CORNWALL, P. L., ABBOTT, R., CRANE, C., POPE, M., & JOHNSON, A. L. (2005) · Psychological Medicine · doi:10.1017/s003329170400282x · Cited by 136
Suicide, suicidality and suicide prevention in affective disorders
Möller, H. J. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s418.15.x · Cited by 127
Self-citation. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder.
Friedman, M. A., Detweiler-Bedell, J. B., Leventhal, H. E., Horne, R., Keitner, G. I., & Miller, I. W. (2004) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.bph052 · Cited by 123
Montgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Self-citationMelander, H., Salmonson, T., Abadie, E., & van Zwieten-Boot, B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.003 · Cited by 117
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0812 · Cited by 116
Möller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107 · cited 3×
“Most of them use the depression mean score difference of a standardised rating scale–for example, the HAM-D or the Montgomery-Åsberg Depression Rating Scale (MADRS) [119] as the outcome criterium for efficacy, some use responder or even remitter rates.”
BackgroundMethodInfluentialSustainable effects on suicidality were found for the Nuremberg alliance against depression
Hegerl, U., Mergl, R., Havers, I., Schmidtke, A., Lehfeld, H., Niklewski, G., & Althaus, D. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0088-z · Cited by 98 · cited 1×
“At least some of these problems can be reduced by awareness campaigns, anti-stigma campaigns, improved education and training of doctors [57,151,155].”
Backgroundde Maat, S., Dekker, J., Schoevers, R., van Aalst, G., Gijsbers-van Wijk, C., Hendriksen, M., Kool, S., Peen, J., Van, R., & de Jonghe, F. (2008) · Depression and Anxiety · doi:10.1002/da.20305 · Cited by 93 · cited 2×
“efficacy in mild and moderate depression as treatment with antidepressants [26,27,55,142].”
BackgroundEfficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients
Schramm, E., Schneider, D., Zobel, I., van Calker, D., Dykierek, P., Kech, S., Härter, M., & Berger, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.013 · Cited by 88 · cited 1×
“specific psychotherapy, ranging from behaviour to psychodynamic therapy, especially focussed psychotherapies like cognitive behaviour therapy (CBT), interpersonal psychotherapy (IPT) and cognitive behavioural analysis system of psychotherapy (CBASP), are gaining an increasingly important position in the treatment of d…”
BackgroundNeuroimaging genetics: New perspectives in research on major depression?
Frodl, T., Möller, H. ‐., & Meisenzahl, E. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01225.x · Cited by 87 · cited 1×
“given this diversity and complexity in the aetiopathogenesis of depression and the pharmacological mechanisms of antidepressants [19,23,41,42,76,178], there is a huge variation of different responses to treatment in general, as well as of different dispositions regarding the question as to which specific antidepressan…”
BackgroundSelf-citationLépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83 · cited 2×
“beneficial efficacy of modern antidepressants in this respect [47,81,94].”
BackgroundMaginn, S., Boardman, A. P., Craig, T. K. J., Haddad, M., Heath, G., & Stott, J. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0751-7 · Cited by 42 · cited 1×
“several studies [77,95,102,106,128,195,204,205,207].”
Cited by
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“For a comprehensive discussion on the topic, see the Position Statement of the EPA on the value of antidepressants in the treatment of unipolar depression (Moller et al. 2012).”
BackgroundSelf-citationJesulola, E., Micalos, P., & Baguley, I. J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.025 · Cited by 379
Lundgren, J. G., Dahlström, Ö., Andersson, G., Jaarsma, T., Kärner Köhler, A., & Johansson, P. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5556 · Cited by 104
Croatto, G., Vancampfort, D., Miola, A., Olivola, M., Fiedorowicz, J. G., Firth, J., Alexinschi, O., Gaina, M. A., Makkai, V., Soares, F. C., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01770-w · Cited by 66
Zemplényi, A., Józwiak-Hagymásy, J., Kovács, S., Erdősi, D., Boncz, I., Tényi, T., Osváth, P., & Voros, V. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04078-9 · Cited by 23
“Health-economics studies have shown that the direct costs of treating depression are much less than the costs and social harm caused by untreated depression [4].”
Background
Metadata
- Authors
- Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-02
- Volume
- 27
- Issue
- 2
- Pages
- 114-128
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W1998805718
- Cited by
- 53
- References
- 51
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.